Source: National Quality Center
MATEC is pleased to announce that our Scholar, Randall McDavid, is now a Graduate of the Clinician Scholars Program! Randall was honored at the Scholars Graduation on Friday, September 5, 2014 in Chicago, Illinois. Randall has demonstrated a strong commitment to providing quality HIV care in his community. Over the past 12 months, he has participated in 22 programs and completed 66.25 hours of training. Randall has demonstrated an enthusiasm and work ethic that is admirable, contagious, and inspiring for those at MATEC Indiana as well as the various practice locations where he works. He receives high accolades from all at MATEC who have worked with him during his past year as one of our outstanding scholars. Please join MATEC in congratulating Randall!
If you are interested in learning more about he Clinician Scholars Program please follow this link — Clinician Scholars Program
The Infectious Disease Clinic at Eskenazi Health is now looking for a Nurse Practitioner to join the team. Please visit http://www.eskenazihealth.edu/careers and search under “Nursing Professionals” at Sidney and Lois Eskenazi Hospital.
Nurse Practitioner Infectious Disease
The Nurse Practitioner in the Infectious Disease Clinic will demonstrate clinical expertise in assessment, diagnostic reasoning, and the therapeutic management of patients. The Nurse Practitioner in Infectious Disease will use research and theoretical principles in implementing therapies that restore health, minimize complications, and manage risk factors as we strive to integrate patient care across the continuum of health care services in collaboration with other healthcare professionals, families, and patients.
- Graduate from a NLN accredited school of nursing with a Master of Science degree in Nursing
- Active Indiana RN license
- Current Indiana registration as a Nurse Practitioner
- Minimum of two years of infectious disease or HIV clinical experience as a Nurse Practitioner preferred
From: Agency for Healthcare Research and Quality (AHRQ)
For the first time, the U.S. Preventive Services Task Force has released an e-book version of its Guide to Clinical Preventive Services, an authoritative source that can help primary care clinicians and patients decide together what preventive services are right for a patient’s needs. The 2014 Guide includes all active Task Force evidence-based recommendations since 2004, including 28 new and updated recommendations since the 2012 version of the Guide.
The e-book is compatible with many readers, including Kindle, Nook, iBook, and Kobo. As a reminder, in addition to the e-book, you can view and download the Guide online or order a print copy of the guide at the AHRQ Publications Online Store. To place a bulk order, please contact AHRQ by email (firstname.lastname@example.org) or phone (toll-free, 800-358-9295).
The Task Force also provides other resources for primary care clinicians, including:
- An up-to-date list of Task Force recommendations, available through the A-Z Topic Index on the Task Force Website.
For more information about the Guide and other Task Force resources, visit: www.uspreventiveservicestaskforce.org.
Judy Collins, BA (Author); Karen Forgash (Contributor)
This tool was designed to illustrate the need for the AETC Program, and Encourage the use of program resources and services by more healthcare professionals. The PDF version can be printed and modified for use in you training activities. The full dimension of the poster is 11″X17″ to view and download this tool click on the following link: http://aidsetc.org/sites/default/files/resources_files/whyaetc_final.pdf
On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10kg to < 25 kg. The first part of this announcement summarizes the changes relevant to the oral formulation and use in pediatric patients. The second part summarizes other general changes to the label.
Oral Powder or Use in Pediatric Patients Label Changes:
- The DOSAGE AND ADMINISTRATION was updated to include information on the oral powder formulation
REYATAZ oral powder must be taken with ritonavir and is not recommended for use in children who weigh less than 10 kg or who weigh 25 kg or more.
Dosage and Administration of REYATAZ Oral Powder in Pediatric Patients
REYATAZ oral powder is for use in treatment-naive or treatment-experienced pediatric patients who are at least 3 months of age and weighing at least 10 kg and less than 25 kg. REYATAZ oral powder must be mixed with food or beverage for administration and ritonavir must be given immediately afterwards. The table below displays the recommended dosage of REYATAZ oral powder and ritonavir.
Table: Recommended Dosage of REYATAZ Oral Powder and Ritonavir in Pediatric Patients (at least 3 months of age and weighing at least 10 kg and less than 25 kg)a
||Daily Dosage of REYATAZ
|Daily Dosage of Ritonavir Oral Solution
|10 kg to less than 15g
||200 mg (4 packets)b
|15 kg to less than 25g
||250 mg (5 packets)b
a The same recommendations regarding the timing and maximum doses of concomitant PPIs and H2RAs in adults also apply to pediatric patients. See Drug Interactions (7) for instructions concerning coadministratrion of acid reducing medications (eg, H2RA or PPIs), and other antiretroviral drugs (eg, efavirenz, tenofovir, and didanosine).
b Each packet contains 50 mg of REYATAZ.
REYATAZ is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 3 months and older weighing at least 10 kg, distributed by Bristol Myers Squibb.
MATEC announces the appointment of Ricardo A. Rivero, MD to the position of Executive Director, effective May 16, 2014. He replaces Barbara Schechtman who is retiring after serving in the position since 1988.
Dr. Rivero has been with MATEC for 11 years, leading the MATEC-Illinois team as the Director. Prior to his time with MATEC, he worked with the American Red Cross, where he had a leadership role within the National Hispanic HIV/AIDS Education and Prevention Program. He also acted as the Executive Director of the Midwest Hispanic AIDS Coalition. Ricardo has both MD and MPH degrees, bringing a strong educational background to the position.
Funded by a federal grant from AIDS United and part of a three-year social innovation cohort research study in collaboration with Johns Hopkins University, The Damien Center’s Linkage to Care (L2C) Program is reaching out to individuals living with HIV and connecting them with the care they need to get and stay healthy. Now in its second year of operation, L2C puts The Damien Center at the forefront of a national movement toward eliminating barriers that keep individuals from getting into and staying in care. The main objective of this grant is to decrease the community viral load by increasing successful transition from diagnosis into treatment and providing the intensive support needed to help clients reengage in and maintain in HIV medical care. To be eligible for L2C, clients must be newly diagnosed and assessed by their Care Coordinator as high-risk for not successfully entering HIV medical care or have been out of HIV medical care for a year or more. At this time, L2C is only available in Region 7. Referrals are to be submitted to Abbe Shapiro, Linkage to Care Program Manager, (317) 632-0123 x263 and email@example.com.
By partnering with key agencies in the communities most impacted by HIV, The Damien Center is able to tailor linkage support to clients’ needs in a culturally sensitive manner. Our sub-grantees are Brother’s United, an agency that serves mainly the Black MSM and transgender community; Women in Motion, an agency that serves mainly women of color; and Indiana Latino Institute, an agency that entered the HIV field through this grant with a desire to address the HIV health disparity within their community. L2C Specialists are housed at these community-based offices to help reduce stigma and improve access to care and treatment. The program also employs a youth-focused Linkage Specialist based at The Damien Center. Clients are enrolled in the program for 18 months and work with both an L2C Specialist and a Care Coordinator. In its first year, the program saw a 93% viral load decrease for clients whose lab data was available both at baseline and three to six months post-enrollment. Fifty-eight clients enrolled in the program during its first year. Thus far this program has been highly effective in both making clients healthier and ultimately reducing their risk of transmitting HIV to others, two of the agency’s overall strategic goals.